Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A 14 amino acid peptide near the amino terminus of human BCAS4.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||20 ug/ml|
|Immunofluorescence (IF)||20 ug/ml|
|Immunohistochemistry (IHC)||5 µg/ml|
|Western Blot (WB)||1-2 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control is NIH-3T3 cell lysate.
PA5-20907 can be used with blocking peptide PEP-1021.
The Breast carcinoma amplified sequence (BCAS4) gene is localized to 20q13, a region that is often amplified in breast cancers. It was isolated by the cloning of a highly overexpressed 1.3 kb transcript from the fusion of the last two exons of the BCAS3 and BCAS4 genes. This BCAS3-BCAS4 fusion transcript is only found in the MCF7 cell line, but the BCAS4 gene is also overexpressed in nine of thirteen breast cancer cell lines. The role of BCAS4 is unknown but its mRNA is highly expressed in thymus, spleen, kidney, brain, and placenta, suggesting BCAS4 plays other roles in multiple tissues.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
BCAS4/BCAS3 fusion; breast carcinoma amplified sequence 4/3 fusion protein; breast carcinoma-amplified sequence 4; RP5-1071L10.2, CNOL